Hughes MD - Search Results

1

Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop.

Albert JM, Ioannidis JP, Reichelderfer P, Conway B, Coombs RW, Crane L, Demasi R, Dixon DO, Flandre P, Hughes MD, Kalish LA, Larntz K, Lin D, Marschner IC, Muñoz A, Murray J, Neaton J, Pettinelli C, Rida W, Taylor JM, Welles SL. Albert JM, et al. Among authors: hughes md. Stat Med. 1998 Nov 15;17(21):2435-62. Stat Med. 1998. PMID: 9819838

2

Evaluating surrogate markers.

Hughes MD, DeGruttola V, Welles SL. Hughes MD, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S1-8. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7552506 Review.

3

Analysis of uncontrolled treatment changes in HIV clinical trails.

Lin HM, Hughes MD. Lin HM, et al. Among authors: hughes md. Stat Med. 1996 Oct 15;15(19):2053-67. doi: 10.1002/(SICI)1097-0258(19961015)15:19<2053::AID-SIM340>3.0.CO;2-Y. Stat Med. 1996. PMID: 8896139 Clinical Trial.

4

Meta-analysis for the evaluation of potential surrogate markers.

Daniels MJ, Hughes MD. Daniels MJ, et al. Among authors: hughes md. Stat Med. 1997 Sep 15;16(17):1965-82. doi: 10.1002/(sici)1097-0258(19970915)16:17<1965::aid-sim630>3.0.co;2-m. Stat Med. 1997. PMID: 9304767

5

Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment.

Ioannidis JP, Bassett R, Hughes MD, Volberding PA, Sacks HS, Lau J. Ioannidis JP, et al. Among authors: hughes md. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Sep 1;16(1):22-30. doi: 10.1097/00042560-199709010-00004. J Acquir Immune Defic Syndr Hum Retrovirol. 1997. PMID: 9377121 Clinical Trial.

6

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.

Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS. Marschner IC, et al. Among authors: hughes md. J Infect Dis. 1998 Jan;177(1):40-7. doi: 10.1086/513823. J Infect Dis. 1998. PMID: 9419168 Clinical Trial.

7

Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials.

Hughes MD. Hughes MD. Stat Med. 2000 Dec 15;19(23):3171-91. doi: 10.1002/1097-0258(20001215)19:23<3171::aid-sim619>3.0.co;2-t. Stat Med. 2000. PMID: 11113952 Review.

8

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM. Demeter LM, et al. Among authors: hughes md. Ann Intern Med. 2001 Dec 4;135(11):954-64. doi: 10.7326/0003-4819-135-11-200112040-00007. Ann Intern Med. 2001. PMID: 11730396 Clinical Trial.

9

Prediction of short-term survival with an application in primary biliary cirrhosis.

Hughes MD, Raskino CL, Pocock SJ, Biagini MR, Burroughs AK. Hughes MD, et al. Stat Med. 1992 Sep 30;11(13):1731-45. doi: 10.1002/sim.4780111307. Stat Med. 1992. PMID: 1485056

10

Power considerations for clinical trials using multivariate time-to-event data.

Hughes MD. Hughes MD. Stat Med. 1997 Apr 30;16(8):865-82. doi: 10.1002/(sici)1097-0258(19970430)16:8<865::aid-sim541>3.0.co;2-d. Stat Med. 1997. PMID: 9160485

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

306 results

Search Page